Janneke E. Jaspers
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Journal: Cancer research
Published: December 17, 2015
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 24, 2015
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.
Journal: Cancer research
Published: December 17, 2014
REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Journal: Nature
Published: February 17, 2014
Monitoring of tumor response to Cisplatin using optical spectroscopy.
Journal: Translational oncology
Published: October 30, 2013
Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.
Journal: Molecular & cellular proteomics : MCP
Published: February 12, 2013
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Journal: Cancer discovery
Published: October 30, 2012
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.
Journal: Molecular & cellular proteomics : MCP
Published: February 28, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026